author-photo

A.C. Privitera

49

Papers

135

Citations

Citation Trend

Filter By

Papers (35) Sort By

Journal Conference Others

AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

2021 Digestive and Liver Disease
Show All
- Source
- Cite
- Save
Citations (0)
PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

2021 Digestive and Liver Disease
Show All
- Source
- Cite
- Save
Citations (0)
AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

2021 Digestive and Liver Disease
Show All
- Source
- Cite
- Save
Citations (0)
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2021 Digestive and Liver Disease
Show All
- Source
- Cite
- Save
Citations (0)
P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

2021 Journal of Crohn's and Colitis
Show All
- Source
- Cite
- Save
Citations (0)
P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

2021 Journal of Crohn's and Colitis
Show All
- Source
- Cite
- Save
Citations (0)
P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease

2021 Journal of Crohn's and Colitis
Show All
- Source
- Cite
- Save
Citations (0)
P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results

2020 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (0)
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study:

2020 United European gastroenterology journal
Show All
- Source
- Cite
- Save
Citations (6)
A Propensity Score Weighted Comparison of Vedolizumab and Adalimumab in Crohn's Disease.

2020 Journal of Gastroenterology and Hepatology
Show All
- Source
- Cite
- Save
Citations (4)